Navigation Links
Osteotech to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
Date:7/30/2009

EATONTOWN, N.J., July 30 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, announced today that its management team is scheduled to present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference at the Millennium Broadway Hotel in New York on Wednesday, August 5, 2009 at 1:15 p.m. (EDT).

A live, listen-only webcast of the presentation can be accessed by visiting the BMO Capital Markets conference website at http://www.bmocm.com/conferences/2009healthcare/webcast/. A replay will be available on the BMO Capital Markets conference website and will be archived for approximately two weeks.

About Osteotech

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing biologic solutions for regenerative medicine to support surgeons and their patients through the development of innovative therapy-driven products that alleviate pain, promote regenerative and biologic healing and restore function. For further information regarding Osteotech or this press release, please go to Osteotech's website at http://www.osteotech.com.


'/>"/>
SOURCE Osteotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. C O R R E C T I O N -- Osteotech, Inc.
2. Osteotech Reports Second Quarter 2009 Financial Results
3. Osteotech Announces Second Quarter 2009 Financial Results Release and Conference Call
4. Osteotech Announces Fourth Quarter and Full Year 2008 Earnings Release and Conference Call; Company to Release Financial Results on Wednesday, March 4, 2009 and Host Call on Thursday, March 5, 2009
5. Osteotech Receives 13485:2003 ISO Certification; Company Meets International Standards for Medical Device Manufacturing
6. Osteotech Expands Senior Management Team; New Executives to Drive Sales Force Strategies and Therapy-Based Solutions
7. Osteotech Reports 2008 Second Quarter Diluted Earnings Per Share of $.10 on Revenues of $27.6 Million
8. Osteotech Announces the Unexpected Passing of Audit Committee Member Leads to Receipt of Nasdaq Deficiency Letter
9. Osteotech Engages BioHorizons as Exclusive Distributor to International Dental Market
10. Osteotech Signs Agreement To Distribute Harvest Technologies BMAC(TM) System
11. Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... ... March 30, 2017 , ... ... educational offerings of corporate finance programs to address the increasingly complex educational needs ... executives increase their knowledge of sophisticated corporate finance and will increase their ability ...
(Date:3/30/2017)... , ... March 30, 2017 , ... ... submitted a letter to President Trump expressing their support for an independent Vaccine ... two Ph.D. scientists and one medical journalist, will hold a press conference at ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... Full Contact ... founder of Pet Protect Law that assists dog owners in creating legally-enforceable ... new owners in taking the natural next step to protect their new companion. Says ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sports Brand EXOUS Bodygear announced today ... normally at $29.97; for the remaining days of March, the price will be only ... a special price of just $10 (regular retail price $19.97). , The special promotional ...
(Date:3/29/2017)... ... March 29, 2017 , ... Patients interested ... Carnegie, OK, from Dr. Jamie Cameron, with or without a referral. The FASTBRACES ... orthodontic treatment. Depending on each patient’s case, treatment with the FASTBRACES system could ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 2017  Experts in the field in alcohol ... Soberlink Systems  as a model for recovery through ... early 2017, concluded that remote blood alcohol monitoring ... recovery." The findings of the expert ... detail a range of variables that are commonplace ...
(Date:3/29/2017)... March 29, 2017  Glenmark Pharmaceuticals, a global ... 301, an investigational fixed-dose combination of mometasone furoate ... twice-daily as a nasal spray being studied for ... are from a recently completed Phase 3 trial ... combination therapy versus mometasone, olopatadine or placebo. ...
(Date:3/29/2017)... 29, 2017 Research and Markets has announced ... report to their offering. ... The global lifestyle drugs market to grow at a ... report, Global Lifestyle Drugs Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
Breaking Medicine Technology: